首页|养正合剂改善结直肠癌XELOX化疗患者免疫状态、毒副反应的效果观察

养正合剂改善结直肠癌XELOX化疗患者免疫状态、毒副反应的效果观察

扫码查看
目的 探寻养正合剂改善结直肠癌XELOX化疗患者免疫状态、毒副反应的效果.方法 回顾性分析 85 例接受XELOX化疗的结直肠癌患者临床资料,根据患者是否接受养正合剂干预分为常规干预组(39 例)以及改良干预组(46 例).常规干预组给予常规营养支持结合快速康复护理,改良干预组在常规干预组的基础之上联合养正合剂治疗.比较两组患者干预前后细胞免疫功能指标(CD3+、CD4+、CD4+/CD8+),癌胚抗原(CEA),糖类抗原 125(CA125),糖类抗原 199(CA199)水平以及毒副反应.结果 干预后,两组患者CD3+、CD4+、CD4+/CD8+水平均高于干预前,且改良干预组CD3+(67.21±7.89)%、CD4+(46.89±8.45)%、CD4+/CD8+(1.89±0.54)高于常规干预组的(61.13±7.45)%、(40.12±5.26)%、(1.46±0.39)(P<0.05).干预后,两组患者CEA、CA125、CA199 水平均较干预前降低,且改良干预组CEA(5.26±1.56)μg/L、CA125(29.17±5.23)U/ml、CA199(32.75±5.36)U/ml均低于常规干预组的(8.14±1.38)μg/L、(35.46±6.14)U/ml、(38.46±6.14)U/ml(P<0.05).改良干预组毒副反应发生率 28.26%显著低于常规干预组的 53.85%(P<0.05).结论 养正合剂应用于结直肠癌患者XELOX化疗中能够有效改善患者化疗后免疫功能,在提升化疗疗效的同时缓解毒副反应,具有较高的应用价值,值得临床借鉴应用.
Observation on effect of Yangzheng Mixture on immune status and side effects in patients with colorectal cancer undergoing XELOX chemotherapy
Objective To explore the effect of Yangzheng Mixture on immune status and side effects in patients with colorectal cancer undergoing XELOX chemotherapy.Methods The clinical data of 85 patients with colorectal cancer undergoing XELOX chemotherapy was retrospectively analyzed.According to presence or absence of Yangzheng Mixture intervention,they were divided into routine intervention group(39 cases)and modified intervention group(46 cases).The routine intervention group received routine nutrition support combined with rapid rehabilitation nursing,and the modified intervention group was combined with Yangzheng Mixture on the basis of the routine intervention group.The levels of cellular immune function indicators(CD3+,CD4+,CD4+/CD8+),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and side effects were compared between the two groups before and after intervention.Results After intervention,the levels of CD3+,CD4+and CD4+/CD8+in both groups were higher than those before intervention;and CD3+of(67.21±7.89)%,CD4+of(46.89±8.45)%and CD4+/CD8+of(1.89±0.54)in modified intervention group were higher than those of(61.13±7.45)%,(40.12±5.26)%and(1.46±0.39)in routine intervention group(P<0.05).After intervention,the levels of CEA,CA125 and CA199 were decreased in both groups compared to those before intervention;and CEA of(5.26±1.56)μg/L,CA125 of(29.17±5.23)U/ml and CA199 of(32.75±5.36)U/ml in modified intervention group were lower than those of(8.14±1.38)μg/L,(35.46±6.14)U/ml and(38.46±6.14)U/ml in routine intervention group(P<0.05).The incidence of side effects in modified intervention group was 28.26%,which was significantly lower than that of 53.85%in routine intervention group(P<0.05).Conclusion The application of Yangzheng Mixture in XELOX chemotherapy can effectively improve the immune function of colorectal cancer patients after chemotherapy,improve the efficacy of chemotherapy while alleviating side effects,which has high application value and is worthy of clinical reference.

Colorectal cancerYangzheng MixtureXELOX chemotherapyImmune statusSide effects

宗琦、姚亚云、黄骞、范玲婕、王梦姣、陈胜东、吕青

展开 >

214200 江苏省宜兴市肿瘤医院放疗科

结直肠癌 养正合剂 XELOX化疗 免疫状态 毒副反应

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(2)
  • 12